Enoxaparin Bioequivalence Study in Acute Coronary Syndrome Patients

• Status: Completed
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Because of their anti-Xa and ease of administration activity, the Low molecular weight heparin represent an attractive alternative to the unfractionated heparin. Several clinical trials have demonstrated that Low molecular weight heparin was more effective than Unfractionated heparin without increasing bleeding complications. Enoxaparin has been the most studied. Its use is recommended.

Demonstrate that Enoxa® is comparable to that of Lovenox® in the anti-Xa activity action.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Monastir
• Collaborator: University Hospital Fattouma Bourguiba
• Treatments: Enoxaparin

Criteria

Inclusion Criteria:

• Age over 18 year old

• With an acute coronary syndrome confirmed

Exclusion Criteria:

• Age less than 18 years

• Persistent ST segment elevation

• Contre indication of enoxaparin and heparin in general.

• Patient participating in another study,

• Pregnant or nursing women

• patients taking an anticoagulant in the last three months,

• Patients with coagulopathy